ABSTRACT
OBJECTIVE: To systematically review the key pints of updated 'Guidelines for Diagnosis and Treatment of COVID-19' and sort out the knowledge about the disease in combination with relevant literatures so as to provide guidance for clinical practice. METHODS: The similarities and differences among the 7 trial editions of 'Guidelines for Diagnosis and Treatment of COVID-19' that were issued by the National Health Commission of the People's Republic of China(NHC) from Jan. 15, 2020 to Mar. 3, 2020 were observed and compared. The features, epidemiological characteristics, diagnosis and treatment programs and prevention strategies for COVID-19 were sorted out in combination with the published literatures that were included in the databases such as Pubmed and CNKI and the latest data of COVID-19 that were released by the authorities like World Health Organization and the Centers for Disease Control and Prevention. RESULTS: In China, COVID-19 has been included in class B notifiable infectious disease, and the prevention and control measures were taken as class A. At present, there is no effective treatment drug, and the supportive treatment is the major treatment strategy, and the oxygen therapy is an extremely important treatment strategy for severe cases. CONCLUSION: Each edition of the Guidelines is drawn on the latest advance in frontier research of the diseases and plays a positive role in guiding the prevention of the epidemic. The high-frequency and large-scale update of the guidelines for diagnosis and treatment may reflect the constantly deepening understanding of the disease.